Weight Loss Medication (Tirzepatide (Mounjaro))

Posted on:

Weight Loss Medication (Tirzepatide (Mounjaro))

Across England, including Cheshire and Merseyside, access to the medication is being phased and prioritised to ensure patients with the greatest clinical need can receive it.

In response to the National Institute for Health and Care Excellence’s (NICE) requirement to make this drug available in Primary Care Settings. The Integrated Care Board (ICB) is in the process of commissioning community/primary care weight loss prescribing services, so that GPs have a point of referral for eligible patients in line with guidelines. As soon as these are available, we will update you. Before this service is in place, we will not be able to refer patients or prescribe this medication.

Please see the Cheshire and Mersey ICB website for more further information: https://www.cheshireandmerseyside.nhs.uk/…/mounjaro…/

The national rollout set by NHS England means access this year is only available to people with at least four of the five health conditions listed below, plus a BMI of at least 40 (BMI to be adjusted for ethnicity*).

– Type 2 diabetes mellitus

– High blood pressure

– Heart disease

– Obstructive sleep apnoea (when your breathing stops and starts while you sleep)

– Abnormal blood fats (dyslipidaemia)